KY-0118

N/A

Report date: 2024/01/10 16:07:35

Base Information

Drug NameKY-0118
Drug Alias NameKY-0118KY0118
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionProgrammed cell death protein 1 blockersInterleukin-2 stimulants
TargetsProgrammed cell death protein 1Interleukin-2
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNovatim Immune Therapeutics (Zhejiang) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNovatim Immune Therapeutics (Zhejiang) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[7] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A